NASDAQ · Drug Manufacturers - Specialty & Generic

TXMD (TXMD) Stock

$2.07 +0.24% NASDAQ: TXMD Healthcare

Valuation

MetricValue
Price$2.07
Market Cap$23.90M
P/E Ratio-39.80
P/B Ratio0.85
P/S Ratio7.18
EPS (TTM)$-0.05
52-Week High$2.95
52-Week Low$0.98
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-3.70%
ROA-2.63%
ROCE-14.81%
Gross Margin-133.33%
Operating Margin-133.33%
Net Margin5.34%
Debt/Equity0.18
Current Ratio2.80

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$70.0M$1.0M$2.0M$3.0M
Operating Profit$-80.0M$1.0M$-9.0M$-5.0M$-4.0M
Net Profit$-172.0M$112.0M$-10.0M$-2.0M$-1.0M
EPS$-25.83$-10.35$-0.74$-0.19$-0.05
Op Margin-3092.8%1.7%-654.6%-270.3%-139.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$169.0M$90.0M$43.0M$39.0M$38.0M
Total Liabilities$263.0M$55.0M$14.0M$11.0M$11.0M
Cash$65.0M$38.0M$4.0M$5.0M$7.0M
Borrowings$198.0M$9.0M$8.0M$7.0M$5.0M

Latest News

TherapeuticsMD: Q1 Earnings Snapshot Associated Press · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-148.0M$-4.0M$-48.0M$1.0M$2.0M
Investing Cash Flow$-2.0M$223.0M$48.0M$0$0
Financing Cash Flow$0$-40.0M$0$0$0
Net Cash Flow$-16.0M$-16.0M$-45.0M$1.0M$2.0M
Free Cash Flow$-148.0M$-4.0M$0$1.0M$2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield11.11%
Quick Ratio3.11
Interest Coverage—
Return 1Y70.18%
Return 3Y-50.64%
Return 5Y-96.12%

Ownership

Insiders Held7.45%
Institutions Held34.01%
Institutions Float Held36.74%
Institutional HolderSharesReport Date
Rubric Capital Management LP1,192,1912026-03-31
Clearline Capital, LP635,2222026-03-31
Squadron Capital Management LLC420,4212026-03-31
Vanguard Capital Management LLC353,6972026-03-31
Tejara Capital Ltd345,8522026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMS $1.51 +3.42% -6.17 $10.00M 0.00%
AYTU $2.28 +3.23% -1.00 $24.49M 0.00%
BFRI $1.17 -4.88% -0.90 $14.98M 0.00%
EKSOEkso Bionics Holdings, Inc. $15.90 -9.86% -2.95 $38.57M 0.00%
ERNA $3.35 -3.46% 0.01 $1.05M 0.00%

About TXMD

TXMD is led by CEO Marlan D. Walker, employs 1 people, headquartered in US, publicly traded since 2007.

TXMD stock trades at $2.07 with a market capitalization of $23.90M. The stock is valued at a price-to-earnings (P/E) ratio of -39.80, price-to-book of 0.85, price-to-sales of 7.18. Over the past 52 weeks the stock has ranged between $0.98 and $2.95, and currently trades 29.8% below its 52-week high.

On profitability, TXMD generates a return on equity (ROE) of -3.70%, return on capital employed of -14.81%, an operating margin of -133.33%, a net profit margin of 5.34%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides